Pages that link to "Q36589865"

The following pages link to Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. (Q36589865):

Displaying 50 items.

• Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (Q26741153) ‎ (← links)
• Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players (Q26765877) ‎ (← links)
• The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients (Q26782449) ‎ (← links)
• Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options (Q26995549) ‎ (← links)
• Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA (Q27011221) ‎ (← links)
• Extracellular alkaline pH leads to increased metastatic potential of estrogen receptor silenced endocrine resistant breast cancer cells (Q27304731) ‎ (← links)
• Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies (Q28072897) ‎ (← links)
• Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant (Q28076777) ‎ (← links)
• Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model (Q28390826) ‎ (← links)
• Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis (Q33624824) ‎ (← links)
• Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. (Q33664216) ‎ (← links)
• Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer (Q33703311) ‎ (← links)
• Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer (Q33992390) ‎ (← links)
• Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population (Q34307263) ‎ (← links)
• Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine (Q34402129) ‎ (← links)
• Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients (Q34551543) ‎ (← links)
• Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients (Q34994963) ‎ (← links)
• MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer (Q35128098) ‎ (← links)
• MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ (Q35144274) ‎ (← links)
• A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer (Q35555115) ‎ (← links)
• Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics (Q35583904) ‎ (← links)
• Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation (Q35689023) ‎ (← links)
• The role of Nanog expression in tamoxifen-resistant breast cancer cells (Q35703398) ‎ (← links)
• A meta-analysis to evaluate the cellular processes regulated by the interactome of endogenous and over-expressed estrogen receptor alpha. (Q35745028) ‎ (← links)
• Role of epigenetic modifications in luminal breast cancer (Q35963443) ‎ (← links)
• Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer (Q35975638) ‎ (← links)
• Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer (Q36088779) ‎ (← links)
• MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy (Q36370545) ‎ (← links)
• Analysis of factors affecting endocrine therapy resistance in breast cancer (Q36502389) ‎ (← links)
• Alteration of GLIS3 gene expression pattern in patients with breast cancer (Q36749993) ‎ (← links)
• Repeated changes of the molecular subtype in gastric metastasis from breast cancer: A case report (Q36824428) ‎ (← links)
• HOX genes: Major actors in resistance to selective endocrine response modifiers (Q36880407) ‎ (← links)
• CCAR1 5' UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance. (Q36979218) ‎ (← links)
• Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma (Q37151107) ‎ (← links)
• Regulation of breast cancer and bone metastasis by microRNAs (Q37259128) ‎ (← links)
• Formal modeling and analysis of ER-α associated Biological Regulatory Network in breast cancer (Q37359952) ‎ (← links)
• Oestrogen receptor negativity in breast cancer: a cause or consequence? (Q37529397) ‎ (← links)
• Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases (Q37580407) ‎ (← links)
• Multidrug-resistant breast cancer: current perspectives (Q37593383) ‎ (← links)
• Molecular mechanisms and mode of tamoxifen resistance in breast cancer (Q37608272) ‎ (← links)
• Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? (Q37631514) ‎ (← links)
• Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells. (Q37687668) ‎ (← links)
• Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer (Q37721802) ‎ (← links)
• miR-221/222: promising biomarkers for breast cancer (Q38093079) ‎ (← links)
• The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy (Q38192017) ‎ (← links)
• Reprimo, a Potential p53-Dependent Tumor Suppressor Gene, Is Frequently Hypermethylated in Estrogen Receptor α-Positive Breast Cancer (Q38623918) ‎ (← links)
• Should endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer? (Q38661501) ‎ (← links)
• Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer (Q38716017) ‎ (← links)
• Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint (Q38748101) ‎ (← links)
• Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations (Q38753738) ‎ (← links)